US2134246A - Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same - Google Patents
Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same Download PDFInfo
- Publication number
- US2134246A US2134246A US149548A US14954837A US2134246A US 2134246 A US2134246 A US 2134246A US 149548 A US149548 A US 149548A US 14954837 A US14954837 A US 14954837A US 2134246 A US2134246 A US 2134246A
- Authority
- US
- United States
- Prior art keywords
- histidine
- ascorbic acid
- acid salts
- manufacture
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- Example 1 310 parts by weight of histidine base and 1'76 parts by weight of ascorbic acid are dissolved in 5,000 parts of water through which a current 01' nitrogen is continuously passed, the water having previously been boiled to remove air and cooled in a current of nitrogen.
- the finished solution can, for instance, be filled into ampoules containing nitrogen which are immediately sealed. These solutions remain permanently colorless. They may even be heated (sterilized) in a current ofsteam without any appreciable change of color.
- Example '2 209.5 parts'by weight of histidine mono-hydrochloride (containing 1 mol. of water of crystallization) and 199 parts by weight of sodium ascorbate are dissolved in 5,000 parts of water free from oxygen, nitrogen being introduced during dissolution. The air is removed from the containers in which the solution is to be stored by evacuation. The solutions remain colorless.
- a package comprising a solution of the ascorbic acid salts of histidine in oxygen free I water in a container excluding oxygen.
- a package comprising a solution of the ascorbic acid salts of histidine in water containing gases free from oxygen in a container excluding oxygen.
- a package comprising a solution ofthe ascorbic acid salts of histidine in water free from oxygen under nitrogen in a container excluding 6.
- a process for the manufacture of stable solutions of the ascorbic acid salts of histidine which comprises preparing a solution of said salts in oxygen free water and packaging said solutio in containers under nitrogen.
Landscapes
- Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Furan Compounds (AREA)
Description
Patented Oct. 25, 1938 UNITED STATES STABLE SOLUTIONS OF ASCORBIC ACID SALTS OF HISTIDINE AND PROCESS FOR THE MANUFACTURE OF SAME Franz Elger, Basel, Switzerland, assignor to Hollmann-La Roche Inc., Nutley, N. J., a corporation of New Jersey No Drawing.
Application June 21, 1937, Serial No. 149,548. In Switzerland July 9, 1936 6 Claims.
If ascorbic acid is neutralized with histidine base, the solutions of the resulting salts are not stable as is evident from the fact that they soon turn raspberry-red to dark orange-brown. If,
for instance, 3.1 grammes of histidine base W mol.) and 1.76 grammes of ascorbic acid mol.) are dissolved in 100 com. of water, the resulting solution of the salt has a pHof 6.0. It very rapidly changes color, first light pink,
10 then to raspberry-red, and finally becomes dark orange-brown. Solutions of other ascorbic acid salts, for instance of sodium ascorbate, or of other histidine salts, such as histidine hydrochloride, having the same pH, do not show this rapid change of color. This is a'property peculiar to the solutions of ascorbic acid salts of histidine. The constitution of the resulting colored compounds has not yet been ascertained.
This change of color can be completely inhibited if the utmost care is taken to prevent access of air during the preparation of the solutions of ascorbic acid salts of histidine and also to protect the finished solutions against access of air. This can be achieved, for instance, by dissolving ascorbic acid and histidine base. or ascorbates and salts of histidine, in the required proportions in water through which, for instance, carbon dioxide or nitrogen has been passed for some time, and preventing access of air to the solutions so prepared, which can be efiected by filling the containers with a gas free from oxygen, or by removing the air therefrom by evacuation.
The stable solutions of the. ascorbic acid salts of histidine are to be used in the treatment of gastroduodenal ulcers by injection. Both the histidine and the ascorbic acid radicals have proven valuable in the treatment of such ulcers as evidenced by the articles of I. F. Volina and R. F. McLaughlin in The Medical Record, New
York City, April 17, 1935. and in the Illinois Medical Journal, January 1936, and the article of P. B. Davidson in Journal of the American Medical Association, vol. 90, page 1014, and the article of Scale Harris, Journal American Medical Association," vol. 91, page 1452.
Example 1 310 parts by weight of histidine base and 1'76 parts by weight of ascorbic acid are dissolved in 5,000 parts of water through which a current 01' nitrogen is continuously passed, the water having previously been boiled to remove air and cooled in a current of nitrogen. The finished solution can, for instance, be filled into ampoules containing nitrogen which are immediately sealed. These solutions remain permanently colorless. They may even be heated (sterilized) in a current ofsteam without any appreciable change of color.
Example '2 209.5 parts'by weight of histidine mono-hydrochloride (containing 1 mol. of water of crystallization) and 199 parts by weight of sodium ascorbate are dissolved in 5,000 parts of water free from oxygen, nitrogen being introduced during dissolution. The air is removed from the containers in which the solution is to be stored by evacuation. The solutions remain colorless.
I claim:
1. A package comprising a solution of the ascorbic acid salts of histidine in oxygen free I water in a container excluding oxygen.
2. A package comprising a solution of the ascorbic acid salts of histidine in water containing gases free from oxygen in a container excluding oxygen.
A package comprising a solution ofthe ascorbic acid salts of histidine in water free from oxygen under nitrogen in a container excluding 6. A process for the manufacture of stable solutions of the ascorbic acid salts of histidine which comprises preparing a solution of said salts in oxygen free water and packaging said solutio in containers under nitrogen.
FRANZ ELGER.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH2134246X | 1936-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
US2134246A true US2134246A (en) | 1938-10-25 |
Family
ID=4567641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US149548A Expired - Lifetime US2134246A (en) | 1936-07-09 | 1937-06-21 | Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same |
Country Status (1)
Country | Link |
---|---|
US (1) | US2134246A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2419230A (en) * | 1942-09-07 | 1947-04-22 | Frances R Ruskin | Therapeutic compositions and method of preparing same |
US2498778A (en) * | 1947-11-10 | 1950-02-28 | Organic Chemicals Inc | Composition to increase the absorption by the body of histamine |
US2539483A (en) * | 1945-03-28 | 1951-01-30 | Simon L Ruskin | Urea ascorbate and complexes containing the same and process for their manufacture |
US2570734A (en) * | 1948-12-30 | 1951-10-09 | Interchem Corp | Stable histidine ascorbate |
US2606903A (en) * | 1944-03-29 | 1952-08-12 | Physiological Chemicals Compan | Ascorbic acid addition compound of sulfathiazole |
US3056491A (en) * | 1958-08-29 | 1962-10-02 | Polaroid Corp | Fluid containers |
US3132154A (en) * | 1953-12-07 | 1964-05-05 | Meyer-Doring Hans | Production of ascorbic acid esters |
US3173580A (en) * | 1962-09-21 | 1965-03-16 | Polaroid Corp | Fluid containers |
US5140043A (en) * | 1989-04-17 | 1992-08-18 | Duke University | Stable ascorbic acid compositions |
US6020367A (en) * | 1997-12-02 | 2000-02-01 | Avon Products, Inc. | Supersaturated ascorbic acid solutions |
US20050154054A1 (en) * | 2004-01-13 | 2005-07-14 | Skinceuticals, Inc. | Stabilized ascorbic acid compositions and methods therefor |
US20090286874A1 (en) * | 2006-03-22 | 2009-11-19 | L'oreal | Anti-aging composition containing phloretin |
-
1937
- 1937-06-21 US US149548A patent/US2134246A/en not_active Expired - Lifetime
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2419230A (en) * | 1942-09-07 | 1947-04-22 | Frances R Ruskin | Therapeutic compositions and method of preparing same |
US2606903A (en) * | 1944-03-29 | 1952-08-12 | Physiological Chemicals Compan | Ascorbic acid addition compound of sulfathiazole |
US2539483A (en) * | 1945-03-28 | 1951-01-30 | Simon L Ruskin | Urea ascorbate and complexes containing the same and process for their manufacture |
US2498778A (en) * | 1947-11-10 | 1950-02-28 | Organic Chemicals Inc | Composition to increase the absorption by the body of histamine |
US2570734A (en) * | 1948-12-30 | 1951-10-09 | Interchem Corp | Stable histidine ascorbate |
US3132154A (en) * | 1953-12-07 | 1964-05-05 | Meyer-Doring Hans | Production of ascorbic acid esters |
US3056491A (en) * | 1958-08-29 | 1962-10-02 | Polaroid Corp | Fluid containers |
US3173580A (en) * | 1962-09-21 | 1965-03-16 | Polaroid Corp | Fluid containers |
US5140043A (en) * | 1989-04-17 | 1992-08-18 | Duke University | Stable ascorbic acid compositions |
US6020367A (en) * | 1997-12-02 | 2000-02-01 | Avon Products, Inc. | Supersaturated ascorbic acid solutions |
US20050154054A1 (en) * | 2004-01-13 | 2005-07-14 | Skinceuticals, Inc. | Stabilized ascorbic acid compositions and methods therefor |
US7179841B2 (en) | 2004-01-13 | 2007-02-20 | L'oreal Usa Creative, Inc. | Stabilized ascorbic acid compositions and methods therefor |
US20090286874A1 (en) * | 2006-03-22 | 2009-11-19 | L'oreal | Anti-aging composition containing phloretin |
US9248082B2 (en) | 2006-03-22 | 2016-02-02 | L'oreal | Anti-aging composition containing phloretin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US2134246A (en) | Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same | |
KR100191873B1 (en) | Stabilized PVP-I Solution | |
DK157168B (en) | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS BASED ON CIS PLATIN (II) DIAMINDICHLORIDE | |
SK10982002A3 (en) | Pharmaceutical composition comprising pemetrexed together with monothioglycerol L-cystein or thioglycolic acid | |
US2187467A (en) | Cevitamate solution | |
JP3243387B2 (en) | Plastic container containing bicarbonate-containing chemicals | |
EP0278674A2 (en) | Sterilization of compositions of limited stability | |
JPS62252722A (en) | Injection containing n-(2-hydroxyethyl)nicotinamide nitrate | |
US3035973A (en) | Gelatin capsule containing calcium dioctyl sulfosuccinate | |
US2473339A (en) | Stable, sterile aqueous solutions of streptomycin and process of making same | |
SE7900774L (en) | STABLE STERILE WATER DISPOSAL OF CISPLATIN | |
KR20110022686A (en) | Stable Aqueous Composition Containing Sulfonamide Compounds | |
NO156675B (en) | PROCEDURE FOR PREPARING A STABLE, CONCENTRATED CISPLATIN SOLUTION. | |
US2266992A (en) | Therapeutic composition | |
US2694487A (en) | Flexibility of catgut sutures | |
SU1025680A1 (en) | Method for preparing galss products for packing medical preparations | |
US2213977A (en) | Pharmaceutical | |
JPS60239414A (en) | Method for suppressing discoloration of etoposide solution | |
JPS62194861A (en) | Liquid drug package | |
US2647853A (en) | Injectable solution of salt of para-aminosalicylic acid | |
US2260004A (en) | Stable soluble magnesium acid citrate | |
US3239420A (en) | Gelatin composition | |
US2063297A (en) | Acid hardening fixing composition and method of preparing the same | |
FI58072C (en) | FOERFARANDE FOER FRAMSTAELLNING AV ETT TORRPREPARAT AV ETT ALKALIMETALLSALT AV DEHYDROEPIANDROSTERONSULFAT FOER PARENTERAL ADMINISTRATION | |
US2354132A (en) | Therapeutic product and process for the manufacture of the same |